Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/43150
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Joris, S | - |
dc.contributor.author | Denys, H | - |
dc.contributor.author | Collignon, J | - |
dc.contributor.author | Rasschaert, M | - |
dc.contributor.author | de Roodenbeke, DT | - |
dc.contributor.author | Duhoux, FP | - |
dc.contributor.author | Canon, JL | - |
dc.contributor.author | Tejpar, S | - |
dc.contributor.author | MEBIS, Jeroen | - |
dc.contributor.author | Decoster, L | - |
dc.contributor.author | Aftimos, P | - |
dc.contributor.author | De Grève, J | - |
dc.date.accessioned | 2024-06-14T08:37:58Z | - |
dc.date.available | 2024-06-14T08:37:58Z | - |
dc.date.issued | 2023 | - |
dc.date.submitted | 2024-06-14T08:33:25Z | - |
dc.identifier.citation | ESMO Open, 8 (6) (Art N° 102041) | - |
dc.identifier.uri | http://hdl.handle.net/1942/43150 | - |
dc.description.abstract | The Belgian Precision initiative aims to maximize the implementation of tumor-agnostic next-generation sequencing in patients with advanced cancer and enhance access to molecularly guided treatment options. Academic tumor-agnostic basket phase II studies are part of this initiative. The current investigator-driven trial aimed to investigate the efficacy of olaparib in advanced cancers with a (likely) pathogenic mutation (germline or somatic) in a gene that plays a role in homologous recombination (HR). | - |
dc.description.sponsorship | This work was supported by pharmaceutical companies AstraZeneca (global) and Merckx for medication supply and financial contributions. Financial support was provided by Kom op tegen Kanker (Stand up to Cancer), the Flemish Cancer Society (project ID: 1145) and the Stichting Tegen Kanker (no grant number). | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER | - |
dc.rights | 2023 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). | - |
dc.subject.other | agnostic NGS | - |
dc.subject.other | olaparib | - |
dc.subject.other | colorectal cancer | - |
dc.subject.other | parathyroid cancer | - |
dc.subject.other | biliary tract cancer | - |
dc.subject.other | BRCA1 | - |
dc.subject.other | BRCA2 | - |
dc.subject.other | CHEK2 | - |
dc.subject.other | ATM | - |
dc.title | Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study | - |
dc.type | Journal Contribution | - |
dc.identifier.issue | 6 | - |
dc.identifier.volume | 8 | - |
local.bibliographicCitation.jcat | A1 | - |
local.publisher.place | RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
local.bibliographicCitation.artnr | 102041 | - |
dc.identifier.doi | 10.1016/j.esmoop.2023.102041 | - |
dc.identifier.pmid | 37852034 | - |
dc.identifier.isi | 001113986700001 | - |
local.provider.type | Web of Science | - |
local.uhasselt.international | no | - |
item.fullcitation | Joris, S; Denys, H; Collignon, J; Rasschaert, M; de Roodenbeke, DT; Duhoux, FP; Canon, JL; Tejpar, S; MEBIS, Jeroen; Decoster, L; Aftimos, P & De Grève, J (2023) Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study. In: ESMO Open, 8 (6) (Art N° 102041). | - |
item.fulltext | With Fulltext | - |
item.contributor | Joris, S | - |
item.contributor | Denys, H | - |
item.contributor | Collignon, J | - |
item.contributor | Rasschaert, M | - |
item.contributor | de Roodenbeke, DT | - |
item.contributor | Duhoux, FP | - |
item.contributor | Canon, JL | - |
item.contributor | Tejpar, S | - |
item.contributor | MEBIS, Jeroen | - |
item.contributor | Decoster, L | - |
item.contributor | Aftimos, P | - |
item.contributor | De Grève, J | - |
item.accessRights | Open Access | - |
crisitem.journal.eissn | 2059-7029 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1.pdf | Published version | 375.25 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.